Alpha Teknova, Inc.

NasdaqGM:TKNO Stock Report

Market Cap: US$431.8m

Alpha Teknova Valuation

Is TKNO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TKNO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TKNO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TKNO's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TKNO?

Key metric: As TKNO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TKNO. This is calculated by dividing TKNO's market cap by their current revenue.
What is TKNO's PS Ratio?
PS Ratio11.7x
SalesUS$36.35m
Market CapUS$431.79m

Price to Sales Ratio vs Peers

How does TKNO's PS Ratio compare to its peers?

The above table shows the PS ratio for TKNO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.2x
CYRX Cryoport
1.6x7.5%US$367.8m
OABI OmniAb
22.7x29.2%US$473.2m
QTRX Quanterix
3.8x14.4%US$452.1m
SLGC Standard BioTools
4.8x16.4%US$396.2m
TKNO Alpha Teknova
11.7x14.1%US$431.8m

Price-To-Sales vs Peers: TKNO is expensive based on its Price-To-Sales Ratio (11.7x) compared to the peer average (8.2x).


Price to Sales Ratio vs Industry

How does TKNO's PS Ratio compare vs other companies in the US Life Sciences Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
ATLN Atlantic International
0.6xn/aUS$250.73m
NOTV Inotiv
0.2x6.1%US$109.00m
SNCE Science 37 Holdings
0.6x17.5%US$34.67m
IPA ImmunoPrecise Antibodies
0.6x19.7%US$10.39m
TKNO 11.7xIndustry Avg. 3.3xNo. of Companies10PS02.85.68.411.214+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TKNO is expensive based on its Price-To-Sales Ratio (11.7x) compared to the US Life Sciences industry average (3.3x).


Price to Sales Ratio vs Fair Ratio

What is TKNO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TKNO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.7x
Fair PS Ratio3x

Price-To-Sales vs Fair Ratio: TKNO is expensive based on its Price-To-Sales Ratio (11.7x) compared to the estimated Fair Price-To-Sales Ratio (3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies